Promising brain metastasis combo trial halted after just one patient
NCT ID NCT05553522
First seen Jan 04, 2026 · Last updated May 08, 2026 · Updated 18 times
Summary
This study aimed to see if combining three drugs (tucatinib, trastuzumab, capecitabine) with precise radiation (SRS) could safely control brain tumors from HER2+ breast cancer. Only one person enrolled before the trial was stopped early. The main goal was to find safe doses and watch for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida, 33176, United States
Conditions
Explore the condition pages connected to this study.